Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Oct 23:4:32.
doi: 10.21037/tbcr-23-45. eCollection 2023.

Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2- metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China

Nino Balanchivadze  1 , Nicholas J Robert  2
Affiliations
Editorial

Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2- metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China

Nino Balanchivadze et al. Transl Breast Cancer Res. .
No abstract available

Keywords: Hormone receptor-positive human epidermal growth factor receptor-2-negative metastatic breast cancer (HR+HER2− MBC); abemaciclib; personalized medicine; tucidinostat.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tbcr.amegroups.org/article/view/10.21037/tbcr-23-45/coif). NB has served on the advisory board for Gilead. NJR is a full-time employee for Ontada. The authors have no other conflicts of interest to declare.

Comment on

  • Transl Breast Cancer Res. 4:10.

Similar articles

See all similar articles

Cited by

References

    1. NCCN Clinical Practice Guidelines in Oncology—Breast Cancer Version 4.2023. Accessed August 31, 2023. Available online: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
    1. Cardoso F, Paluch-Shimon S, Senkus E, et al. ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020;31:1623-49. 10.1016/j.annonc.2020.09.010 - DOI - PMC - PubMed
    1. Jiang Z, Li J, Chen J, et al. Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022. Transl Breast Cancer Res 2022;3:13. 10.21037/tbcr-22-21 - DOI - PMC - PubMed
    1. Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med 2016;375:1925-36. 10.1056/NEJMoa1607303 - DOI - PubMed
    1. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016;375:1738-48. 10.1056/NEJMoa1609709 - DOI - PubMed

Publication types